Leukemia, Myeloid, Acute Clinical Trials

213 clinical trials for Leukemia, Myeloid, Acute across international registries, including 24 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• eHealth Mindfulness-based Music Therapy Intervention for Patients Undergoing Stem Cell Transplantation — RECRUITING · NA
• A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) — RECRUITING · PHASE3
• A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring — RECRUITING · PHASE1
• Toxicity Genetic Determinants and Response to Azacitidine and Venetoclax in AML — RECRUITING
• CD33KO-HSPC Infusion Followed by CART-33 Infusion(s) for Refractory/Relapsed AML — RECRUITING · PHASE1
• Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome — RECRUITING · PHASE2
• Single Arm Study of Post-transplant Azacitidine and Chidamide for Prevention of Acute Myelogenous Leukemia Relapse — RECRUITING · PHASE1
• A Study of JNJ-90189892 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms — RECRUITING · PHASE1
• MB-dNPM1-TCR.1 in Relapsed/Refractory AML — RECRUITING · PHASE1
• Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia — RECRUITING · PHASE1
• A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1) — RECRUITING · PHASE1
• CART123 T Cells in Relapsed or Refractory CD123+ Hematologic Malignancies: A Dose Escalation Phase I Trial — RECRUITING · PHASE1
• A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome — RECRUITING · PHASE1
• Venetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of R/R AML — RECRUITING · PHASE2
• DFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia — RECRUITING · PHASE1
• Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia — RECRUITING · PHASE1
• Daunorubicin + Cytarabine + Venetoclax in de Novo AML — RECRUITING · NA
• Registry of Myelodysplastic Syndromes and Therapy-related Acute Myeloid Leukemia — RECRUITING
• Phase I Clinical Study: BG1805 Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia — RECRUITING · PHASE1
• VCA Regimen Followed by D-MAG Regimen on the Treatment of Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) — RECRUITING · PHASE2
• Genetic Landscape in Women with Metastatic Ovarian Cancer Before and During Treatment with PARP Inhibitors — RECRUITING · NA
• Venetoclax Combined with Intensive Therapy for Acute Myeloid Leukemia Patients with Lower Early Peripheral Blast Clearance Rate After Standard Induction Therapy — RECRUITING · NA
• Chidamide Prevents Recurrence of High-risk AML After Allo-HSCT — RECRUITING · PHASE1
• Decitabine Plus mBU/CY for High Risk Acute Leukemia With MRD Pre-HSCT — RECRUITING · PHASE2
• A Prospective Single-Arm Study of VABu Conditioning Regimen in Allo-HSCT for Low-Performance or High-Comorbidity AML Patients in CR1 — NOT_YET_RECRUITING · NA
• Electronic Health Mindfulness-based Music Therapy Intervention for Patients Undergoing Allogeneic Stem Cell Transplantation — COMPLETED · NA
• A Study of JNJ-89853413 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms — ACTIVE_NOT_RECRUITING · PHASE1
• Venetoclax in Association With 3+7 and Midostaurin in FLT3-mutated Acute Myeloid Leukemia — NOT_YET_RECRUITING · PHASE1
• Trial of Revumenib Plus FLA Chemotherapy for Children With Relapsed or Refractory NUP98-rearranged AML." — NOT_YET_RECRUITING · PHASE2
• A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies — ACTIVE_NOT_RECRUITING · PHASE1
• Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation — ACTIVE_NOT_RECRUITING · PHASE3
• Study to Compare Azacitidine Plus Pevonedistat Versus Azacitidine in Patients With Acute Myeloid Leukemia Not Eligible for Standard Chemotherapy — ACTIVE_NOT_RECRUITING · PHASE3
• Study Protocol: Study on Incidence and Risk Factors of Mold Infections in Children During Leukemia Treatment — COMPLETED
• Clinical Trial to Assess the Safety and Tolerability of the Combination of Low-dose Cytarabine or Azacitidine Plus Venetoclax and Quizartinib in Newly Diagnosed AML Patients Aged Equal or More Than 60 Years Old — COMPLETED · PHASE1
• Cusatuzumab in Combination With Background Therapy for the Treatment of Participants With Acute Myeloid Leukemia — ACTIVE_NOT_RECRUITING · PHASE1
• A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy — ACTIVE_NOT_RECRUITING · PHASE2
• An Efficacy and Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy in Chinese Participants With Acute Myeloid Leukemia in Complete Remission — ACTIVE_NOT_RECRUITING · PHASE2
• High- Fiber/ Low-fat Diet for Prevention of Recurrent Clostridioides Difficile Infection in Oncology — COMPLETED · NA
• CD34+ Transplants for Leukemia and Lymphoma — NOT_YET_RECRUITING · PHASE2
• A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy — ACTIVE_NOT_RECRUITING · PHASE1
• Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage — TERMINATED · PHASE3
• Chimeric Antigen Receptor Treatment Targeting CD70 (SEVENTY) — NOT_YET_RECRUITING · PHASE1
• Automated vs Manual Flow-cytometry Gating for Measurable Residual Disease in Acute Myeloid Leukaemia (DUALFLOW) — NOT_YET_RECRUITING
• Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML) — COMPLETED · PHASE3
• Study of Liposomal Annamycin in Combination With Cytarabine for the Treatment of Subjects With Acute Myeloid Leukemia (AML) — COMPLETED · PHASE1
• A Study to Assess the Effect of CC-95251 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndromes — TERMINATED · PHASE1
• Single Arm Study of Azacitidine and Venetoclax for Treatment of Newly Diagnosed Fit Acute Myeloid Leukemia Patients — COMPLETED · NA
• Post-transplant Flotetuzumab for AML — COMPLETED · PHASE1
• Study to Evaluate Safety and Tolerability of CC-91633 (BMS-986397) in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-Risk Myelodysplastic Syndromes — TERMINATED · PHASE1
• A Study of Cusatuzumab Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Candidates for Intensive Chemotherapy — ACTIVE_NOT_RECRUITING · PHASE2

Refine this search